Drug Trial Radar · NCT05522387
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
11
Actual
Start
Feb 21, 2023
Primary completion
Jun 5, 2024
Study completion Jul 5, 2024
Sponsor
- Lead sponsor
- Inmune Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 55 years, up to 86 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this Phase 2 Open Label study is to evaluate long-term safety, tolerability, and efficacy of XPro1595 on measures of cognition, function and brain quality in individuals with Alzheimer's Disease.
Conditions
- Alzheimer Disease
- Dementia
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Tauopathies
- Neurodegenerative Diseases
- Neurocognitive Disorders
- Mental Disorders
Interventions
XPro1595Drug
Each enrolled patient will be treated with 1.0 mg/kg of XPro1595 as a subcutaneous injection once a week for 55, or 74 weeks, for a total exposure to XPro1595 of up to 78 weeks (18 months), depending on their previous study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants who experience adverse events and serious adverse eventsTime frame: Weeks 55, or 74 in the OLE Study
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
KaRa MINDS
Macquarie Park, New South Wales, Australia
Neuro Trials Victoria Pty Ltd T/A NeuroCentrix
Carlton, Victoria, Australia
Austin Health
Ivanhoe, Victoria, Australia
Australian Alzheimer's Research Foundation
Perth, Western Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.